<DOC>
	<DOCNO>NCT02791308</DOCNO>
	<brief_summary>The purpose study compare safety efficacy profile Watson Laboratories , Inc. 's Pimecrolimus Cream , 1 % Valeant Pharmaceuticals North America LLC 's Elidel® ( pimecrolimus ) Cream , 1 % , demonstrate superior efficacy two active cream placebo ( Vehicle test product ) , treatment mild moderate atopic dermatitis .</brief_summary>
	<brief_title>Study Equivalence Generic Pimecrolimus Cream 1 % Elidel® 1 % Subjects With Mild Moderate Atopic Dermatitis</brief_title>
	<detailed_description>Pimecrolimus cream , 1 % calcineurin inhibitor immunosuppressant . Pimecrolimus inhibit T cell activation block transcription early cytokine . Pimecrolimus cream , 1 % indicated second-line therapy short-term non-continuous chronic treatment mild-to-moderate atopic dermatitis non-immunocompromised adult child 2 year age old fail respond adequately topical prescription treatment , treatment advisable . This study conduct evaluate clinical bioequivalence sponsor 's formulation Pimecrolimus Cream , 1 % , Test product , Elidel Cream , 1 % , Reference product . A vehicle control arm include demonstrate Test Reference product active establish study sufficiently sensitive detect difference product .</detailed_description>
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<mesh_term>Pimecrolimus</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Willing able provide write informed consent/assent study . Nonimmunocompromised male female age 12 year old . A clinical diagnosis mild moderate atopic dermatitis fail respond adequately topical prescription treatment atopic dermatitis , subject use treatment deem inadvisable . A diagnosis atopic dermatitis least 3 month . A baseline Investigator 's Global Assessment ( IGA ) disease severity mild moderate ( score 2 3 ) . An affected area atopic dermatitis involvement least 5 % body surface area ( BSA ) Visit 2/Day 1 ( Baseline ) , define criterion Hanifin Rajka ( 1980 ) . Treatment bland emollient least 7 day prior Visit 2/Day 1 ( Baseline ) . Agree adhere protocolspecified requirement concomitant therapy restriction . Willing avoid constant sun exposure use tan booth UV light source participation study . In general good health , nonimmunocompromised , free clinically significant disease , atopic dermatitis , might interfere study evaluation . Willing able understand comply requirement study , apply study medication instruct , return require study visit , comply therapy prohibition , complete study . Female subject childbearing potential ( exclude woman surgically sterilize [ hysterectomy , bilateral tubal ligation , bilateral ovariectomy ] postmenopausal least 1 year ) must negative urine pregnancy test must willing use medically accept method contraception study . The following consider acceptable method birth control purpose study : oral contraceptive , contraceptive patch , contraceptive implant , vaginal contraceptive , double barrier method ( e.g. , condom spermicide ) , contraceptive injection ( DepoProvera® ) , intrauterine device ( IUD ) , hormonal IUD ( Mirena® ) , Essure® permanent birth control , abstinence document second acceptable method birth control subject become sexually active . Subjects enter study hormonal contraceptive must method least 90 day prior study continue method duration study . Subjects use hormonal contraception stop must stop less 90 day prior Visit 1 .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>